Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.67 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.67 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.67 |
| ▸ | FPR2 | P25090 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.63 |
| ▸ | CTSL | P07711 | 2/20 | 0.62 |
| ▸ | CTSS | P25774 | 2/20 | 0.62 |
| ▸ | CTSK | P43235 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | F2 | P00734 | 1/20 | 0.60 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.59 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.59 |
| ▸ | CTSB | P07858 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7039089 | 1.00 | ATM (0.67) | ATMITGB3ITGA2BFPR2KMT2A | |
| SCHEMBL9716776 | 1.00 | ATM (0.67) | ATMITGB3ITGA2BFPR2KMT2A | |
| SCHEMBL7044293 | 1.00 | ATM (0.67) | ATMITGB3ITGA2BFPR2KMT2A | |
| SCHEMBL9716778 | 1.00 | ATM (0.67) | ATMITGB3ITGA2BFPR2KMT2A | |
| SCHEMBL7317573 | 0.95 | HDAC8 (0.64) | ATMITGB3ITGA2BFPR2HDAC8 | |
| SCHEMBL14684392 | 0.95 | HDAC8 (0.64) | ATMITGB3ITGA2BFPR2HDAC8 | |
| SCHEMBL8569421 | 0.92 | ALDH1A1 (0.65) | ATMITGB3ITGA2BKMT2AHDAC8 | |
| SCHEMBL10706226 | 0.92 | ATM (0.60) | ATMITGB3ITGA2BFPR2KMT2A | |
| SCHEMBL2406036 | 0.92 | ALDH1A1 (0.65) | ATMITGB3ITGA2BKMT2AHDAC8 | |
| SCHEMBL11059108 | 0.91 | CTSL (0.60) | ATMITGB3ITGA2BFPR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3186224-B1 | SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS | HOFFMANN LA ROCHE (CH) | 2021-04-21 | — | — | EP | disclosed |
| CN-107001259-B | Substituted azetidine derivatives as TAAR ligands | 豪夫迈·罗氏有限公司 | 2019-12-06 | — | — | CN | disclosed |
| US-10023559-B2 | Substituted azetidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2018-07-17 | — | — | US | disclosed |
| CN-105473575-B | Benzimidazolyl-methylurea derivatives as ALX receptor agonists | 爱杜西亚药品有限公司 | 2017-11-24 | — | — | CN | disclosed |
| CN-107001259-A | Substituted azetidine derivatives as TAAR ligands | 豪夫迈·罗氏有限公司 | 2017-08-01 | — | — | CN | disclosed |
| EP-3186224-A1 | SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS | F. Hoffmann-La Roche AG (CH) | 2017-07-05 | — | — | EP | disclosed |
| EP-3030560-B1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-06-21 | — | — | EP | disclosed |
| US-9663473-B2 | Benzimidazolyl-methyl urea derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-05-30 | — | — | US | disclosed |
| US-20170144994-A1 | SUBSTITUTED AZETIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20160200686-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-07-14 | — | — | US | disclosed |
| EP-3030560-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd (CH) | 2016-06-15 | — | — | EP | disclosed |
| WO-2016030310-A1 | SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-03-03 | — | — | WO | disclosed |
| WO-2015019325-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-02-12 | — | — | WO | disclosed |
| EP-2544702-A1 | BRIDGED LIPOGLYCOPEPTIDES THAT POTENTIATE THE ACTIVITY OF BETA-LACTAM ANTIBACTERIALS | Merck Sharp & Dohme Corp. (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-0659737-B1 | Catecholamine surrogates useful as beta 3 agonists | BRISTOL MYERS SQUIBB CO (US) | 2003-03-26 | — | — | EP | disclosed |
| US-5776983-A | ANTIDIABETIC AGENTS, OBESITY, GASTROINTESTINAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-07 | — | — | US | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023559-B2 | Substituted azetidine derivatives | HTR1B, MTNR1B, DRD2 | ATM 2199/4885ITGB3 4573/4885ITGA2B 4075/4885 |
| US-20170144994-A1 | SUBSTITUTED AZETIDINE DERIVATIVES | HTR1B, MTNR1B, DRD2 | ATM 2199/4885ITGB3 4573/4885ITGA2B 4075/4885 |
| US-20160200686-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | UTS2R, ADORA3, P2RX7 | ATM 3326/4885ITGB3 3095/4885ITGA2B 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.